CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment
ConclusionCYP2C19*3 polymorphism could be an important predictive factor of HPR and ischemic cardiovascular adverse events after clopidogrel treatment.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Xumin Hou, Wenzheng Han, Qian Gan, Yuan Liu, Weiyi Fang Tags: RESEARCH ARTICLE Source Type: research
More News: Cardiology | Cardiovascular | Clopidogrel | Coronary Heart Disease | Genetics | Heart | Heart Disease | Laboratory Medicine | Plavix | Study